Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in ...

Over more than eight years of monitoring, getting familiar with the EU CTR, conducting trial submissions activities, etc., ...

And yet, data science is now poised to usher in a level and acceleration of progress that even life sciences have never ...

We’ll hear from speakers representing Syneos Health, Flagship Pioneering, and IPSEN on pharma dealmakers’ 2025 intentions, ...

But for an industry in which 46 recalls is 46 too many, given the potentially immense costs these incidents can exact, the ...

Johnson & Johnson has agreed to take over Intra-Cellular Therapies in a deal worth up to $14.6 billion – the second biopharma ...

Each year at the JP Morgan Healthcare Conference, life sciences leaders congregate in San Francisco’s Union Square to network ...

This morning, the UK pharma group confirmed it had signed an agreement to buy privately-held IDRx for $1 billion upfront, ...

Metsera's lead asset is MET-097i, billed as an ultra-long-acting GLP-1 receptor agonist with a profile that could challenge ...

The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...

Solution: EVERSANA created an AI-enabled omnichannel solution to inform and empower HCPs and patients more effectively. The ...

Novartis has responded to the inclusion of its heart failure blockbuster Entresto on the list of the first 10 drugs that will be subject to Medicare pricing negotiations, claiming that the move ...